Press Releases

HepaLife Expands Management Team on Heels of Favorable Outcomes of First-of-Its-Kind Bioartificial Liver Device

HepaLife Appoints Dr. Robert Tuttle as Vice President of Research and Development, a Pioneering Cell and Tissue Culture Biologist, with Three FDA-Approved Human Therapeutics and Seven in Clinical Trials


HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) is pleased to announce the addition of Dr. Robert Tuttle as Vice President of Research and Development to assist the Company with development of the first-of-its-kind bioartificial liver device, which, in recent weeks, has mimicked key functions of the liver and surpassed major cell biology and biomechanical milestones.

"I'm honored to welcome Dr. Tuttle as Vice President of Research and Development," commented Mr. Frank Menzler, President and CEO of HepaLife Technologies, Inc. "Dr. Tuttle's appointment follows important research and development successes at HepaLife, prompting the expansion of our scientific and management capabilities."

Last week, HepaLife announced favorable early test results of the Company's proprietary bioreactor system, the main mechanical component of its patented bioartificial liver device, which successfully replicated the liver's key function -- removal of toxic ammonia and synthesis of urea. Researchers consider this ability vital to successfully replicating the human liver's function in an artificial liver device.

(View HepaLife's April 30, 2007 press release announcing HepaLife achieves major milestone in development of artificial liver device:

In early tests of HepaLife's proprietary bioreactor, researchers seeded the system with the Company's patented PICM-19 liver cells, which last month significantly outperformed the world's most widely used human liver cell line and successfully mimicked the liver's key metabolic functions.

(View HepaLife's April 10, 2007 press release and photographs: PICM-19 cells mimic human liver's responses and significantly outperform world's most widely-used liver cell line:

"The early performance success of our proprietary bioreactor system follows highly favorable research findings of HepaLife's patented PICM-19 liver cell line," explained Mr. Menzler. "Together, these excellent outcomes of our cell line and bioreactor system mark significant achievements for HepaLife's bioartificial liver device, currently under development.

"I look forward to leveraging Dr. Robert Tuttle's extensive research knowledge and practical commercial expertise, as we fully exploit these most important biological and mechanical milestones in development of the world's first-of-its-kind bioartificial liver device."

Robert Tuttle, Ph.D.

With three FDA-approved human therapeutics and seven in clinical trials, Dr. Robert Tuttle is widely regarded as an innovative, pioneering cell and tissue culture biologist, with over 25 years of scientific research and commercial development experience.

Earlier this year, Dr. Tuttle joined HepaLife's Scientific Advisory Board, providing important guidance on the Company's primary research and development projects. As Vice President of Research and Development at HepaLife, Dr. Robert Tuttle will devote his efforts to HepaLife on a part-time permanent basis as of May 2007, undertaking key initiatives for scale-up and further development of the Company's patented cell lines:

        --  PBS-1 cell line for potential use in influenza vaccine
            production; and

        --  PICM-19 liver cell line for use in in-vitro toxicology
            testing platforms and incorporation into the
            first-of-its-kind bioartificial liver device.

Previously, Dr. Tuttle served as Vice President Manufacturing for Genetix Pharmaceuticals, where he successfully led the cGMP manufacturing of the first clinical recombinant Lentivirus biologic for hemophilia gene therapy.

Between 2000 through 2004, Dr. Robert Tuttle performed pioneering research in the Biodefense Medical Systems Department of the Battelle Memorial Institute. Among significant research achievements during his tenure at Battelle, Dr. Tuttle successfully invented and patented an avian coccidiosis vaccine, and further invented the production process for a new, better, safer recombinant anthrax protective vaccine.

Dr. Robert Tuttle also served as the Director of Biologics for Novopharm Biotech between 1997 and 2000, during which time he invented processes to manufacture second entry biologics (Bio-Generics), such as TPA and EPO, and a new, better formulation of paclitaxel (Taxol(R)) for first line cancer therapy. Taxol(R) is the first anti-cancer agent to surpass $500 million in U.S. sales, and since FDA approval has generated over $10 billion in revenues.

While at Immunomedics and Cytogen between 1991 and 1996, Dr. Robert Tuttle scaled up and manufactured six of the first clinical monoclonal antibodies for in vivo colorectal, prostate and lymphoma cancer imaging and therapies. Earlier in his career, Dr. Tuttle directed manufacture and modernization of the commercial plasma proteins at CSL in Kankakee, Illinois, including the invention of much-needed PCR-grade albumin, and scaled up the first FDA-approved tissue engineered living skin equivalent at Organogenesis in Cambridge, Massachusetts.


HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) is a biotechnology company focused on the identification and development of cell-based technologies and products.

Current cell-based technologies under development by HepaLife include 1) the first-of-its-kind artificial liver device, 2) proprietary in-vitro toxicology and pre-clinical drug testing platforms, and 3) novel cell-culture based vaccine production to protect against the spread of influenza viruses among humans, including potentially the high pathogenicity H5N1 virus.

For additional information, please visit

To receive future press releases via email, please visit:

To view the full HTML text of this release, please visit:

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including, but not limited to, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that HepaLife will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at The Company makes no commitment to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Source: HepaLife Technologies, Inc.